.jpg)
1 hour ago
3
Article content
- From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8
- Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9
- Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14
- A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” | ||||
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. | ||||
GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT | ||||
GALDERMA | ||||
Article content
Therapeutic Dermatology: Latest updates across atopic dermatitis and acne
Article content
Four presentations on Nemluvio (nemolizumab), the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31, will explore its efficacy and safety in different patient populations with moderate-to-severe atopic dermatitis.1-4,15-17 This includes a late-breaking presentation assessing the pharmacokinetics, safety and efficacy of nemolizumab in pediatric patients (aged 2 to 11 years) on Saturday, March 28 at 10:24-10:36 AM MDT / 5:24-5:36 PM CET in Bellco Theatre 3.1 Additionally, an oral presentation of post hoc data from the ARCADIA long-term extension trial, taking place on Saturday, March 28 at 2:10-2:15 PM MDT / 9:10-9:15 PM CET in Lobby C, Poster Center 2, will look at the long-term maintenance of itch and skin responses with Nemluvio up to 104 weeks.2 Two other posters will display data on Nemluvio’s long-term efficacy and safety up to two years in adolescents, and in patients with partial and minimal skin response at 16 weeks.3,4 Our product theater on Sunday, March 29 at 10:30-11:15 AM MDT / 6:30-7:15 PM CET in Theatre 1 will delve into the critical role of neuroimmune interactions in atopic dermatitis and prurigo nodularis, focusing on how targeted IL-31 treatment can improve patient outcomes.
Article content
Galderma will also present four e-posters on AKLIEF (trifarotene) cream, showcasing decades of innovation behind four generations of retinoids, including fourth-generation trifarotene, its role in acne and skin health, and its molecular design.7,8 Real-world data will further evaluate its impact on acne outcomes and skin quality through personalized regimens and assess its efficacy and safety for facial and truncal acne in Indian patients.5,6Dermatological Skincare: Nine presentations spanning sensitive skin, acne, eczema-prone and mature skin Two oral presentations will be delivered at the congress: one exploring how high-risk factors for sensitive skin can be identified through artificial intelligence (Saturday March 28 at 1:05-1:10 PM MDT / 8:05-8:10 PM CET in Lobby C, Poster Center 2), and another to share results from a survey of dermatology practitioners on post-isotretinoin acne management (Sunday March 29 at 3:10-3:15 PM MDT / 11:10-11:15 PM CET in Lobby C, Poster Center 1).9,18 Five e-posters will investigate the properties of Galderma’s Cetaphil portfolio in different skin types, including the time to itch relief with Cetaphil Restoraderm Eczema Soothing Moisturizer and Restoraderm Eczema Rapid Relief Cream for patients with eczema-prone skin, its efficacy in mature and aging skin, its blendability with Sun Protection Factor across a range of skin tones, and the mildness of Cetaphil Gentle Skin Cleanser.19-21 Ahead of AAD, Galderma will host the Cetaphil Innovation Forum 2026 in collaboration with Galderma’s Global Sensitive Skincare Faculty bringing together healthcare professionals from around the globe to share how innovative biology-driven solutions, including AM/PM Serums and Skin Activator Hydrating & Firming Line, can improve skin health by mitigating two key biological drivers of skin aging: oxidative stress and cellular senescence.Together, these strategies support a broader vision of skin longevity and resilience over time.
Article content
Article content
Injectable Aesthetics: Exploring the ability of different treatment modalities to address needs across the face and body
Article content
Five e-posters will share the latest development updates from Galderma’s injectable aesthetics portfolio, including data:
Article content
- On the company’s versatile Restylane hyaluronic acid portfolio, with e-posters on Restylane Lyft™ for augmentation of the chin region, Restylane Shaype™* in enhancing the jawline, Restylane Contour™* in the correction of temple hollowing, and Restylane Skinboosters™* in smoothing wrinkles in the décolletage.10-13
- Investigating outcomes with RelabotulinumtoxinA*, Galderma’s ready-to-use liquid neuromodulator manufactured with PEARL™Technology, across different age groups when treating moderate-to-severe frown lines and crow’s feet.14
Article content
More details on Galderma’s scientific presentations at AAD can be found here.
Article content
*RelabotulinumtoxinA, Restylane Skinboosters, and Restylane Shaype for the jawline are investigational products not approved in the United States.
Article content
About Galderma
Article content
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Article content
AKLIEF Important Safety Information
Article content
Indication: AKLIEF® (trifarotene) cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF cream were application site irritation, application site pruritus (itching), and sunburn.
Article content
Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.
English (US)